Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis.
AffiliationGynaecology Oncology Research Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractBody mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type.
CitationBody mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. 2010, 19 (12):3119-30 Cancer Epidemiol Biomarkers Prev
JournalCancer Epidemiology, Biomarkers & Prevention
- Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
- Authors: Chang SC, Lacey JV Jr, Brinton LA, Hartge P, Adams K, Mouw T, Carroll L, Hollenbeck A, Schatzkin A, Leitzmann MF
- Issue date: 2007 Apr
- Glycaemic index, glycaemic load and risk of endometrial cancer: a prospective cohort study.
- Authors: Silvera SA, Rohan TE, Jain M, Terry PD, Howe GR, Miller AB
- Issue date: 2005 Oct
- Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
- Authors: McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, Gansler T, Thun MJ, Calle EE
- Issue date: 2008 Jan
- Hormone replacement therapy and cancer risk.
- Authors: Mahavni V, Sood AK
- Issue date: 2001 Sep
- Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study.
- Authors: Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE
- Issue date: 2004 Feb